AbbVie Header AbbVie Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AZTIQ PHARMA","sponsor":"Alvogen","pharmaFlowCategory":"D","amount":"$350.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aztiq Buys 17% Stake in Alvogen US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"ICELAND","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by AZTIQ PHARMA

    Menu

    AZTIQ PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              AZTIQ PHARMA

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Iceland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aztiq Buys 17% Stake in Alvogen US

              Details:

              Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.

              Lead Product(s): Lisinopril

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Zestril

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Alvogen

              Deal Size: $350.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition June 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
              Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.
              Post Enquiry
              POST ENQUIRY